High-dose naltrexone therapy and dietary counseling for obesity

James E. Mitchell, John E. Morley, Allen S Levine, Dorothy K Hatsukami, Mary Gannon, David Pfohl

Research output: Contribution to journalArticlepeer-review

93 Scopus citations


There is considerable evidence that antagonism of the endogenous opioids will suppress food intake in a variety of animal species. The authors report a double-blind, placebocontrolled trial of the long-acting, orally active narcotic antagonist naltrexone in the promotion of weight loss in obese male subjects who were also undergoing dietary counseling for weight reduction. Subjects received medication (naltrexone, 300 mg/day or placebo) for 8 weeks following an initial 2-week single-blind placebo phase. The results failed to demonstrate an advantage for the active drug. However, the naltrexone was associated with hepatotoxicity when used at this dosage in this population.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalBiological Psychiatry
Issue number1
StatePublished - Jan 1987

Fingerprint Dive into the research topics of 'High-dose naltrexone therapy and dietary counseling for obesity'. Together they form a unique fingerprint.

Cite this